Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 8412345...102030...Last »

Three Small CRISPR Biotechs That Could Cure 10,000 Diseases

Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.

Read More »

Bristol-Myers’ Lung Cancer Combo Wows in Phase III

Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.

Read More »

EyeGate’s Eye Drug Fails Phase II Test

EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.

Read More »

Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015

Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.

Read More »

Anika Therapeutics Announces Strategic Collaboration

Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.

Read More »

Roche Cuts Early, Late-Stage Drug Candidates

First reported by FierceBiotech, Roche’s financial reports indicated the company was cutting a total of four drugs: One late-stage product and three drugs in Phase I development.

Read More »

Potential blood test for Alzheimer’s shows promise

Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease.

Read More »

Vertex picks CF triple combos for Phase III trials

Vertex Pharmaceuticals selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients.

Read More »

North Korea threats spur U.S. search for new radiation therapies

The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.

Read More »

Bellicum’s cancer drug trials on clinical hold

Bellicum Pharmaceuticals Inc. said the FDA placed a clinical hold on U.S. trials of the company’s experimental cancer drug after three cases of brain disease linked to head trauma.

Read More »

Global cancer survival rates improve, but wide gaps remain

Cancer patients’ survival prospects are improving – even for some of the deadliest types such as lung cancer – but there are huge disparities between countries, particularly for children, according to a published study.

Read More »

Pfizer Confirms Neuroscience Cuts, Shelves Another Four Early-Stage Projects

Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.

Read More »

Eisai and Boston University School of Medicine Announce Research Collaboration to Study the Effects of Alzheimer’s Disease-associated Genetic Variants on Brain

Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.

Read More »

Corbus CF drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function.

Read More »

Scientists use pocket-size device to map human genetic coder

Scientists have assembled the most complete human genome to be mapped with a single technology using a new pocket-size portable DNA sequencer, which they say could one day make genome mapping quick and simple enough to do at home.

Read More »

AstraZeneca’s three-in-one inhaler helps COPD patients in clinical study

AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late-stage trial that could challenge GlaxoSmithKline’s new three-in-one inhaler.

Read More »

Flu deaths may be less likely with annual vaccination

Seniors who get a flu shot every year are less likely to be hospitalized with severe influenza infections or to die from them than those who get vaccinated only sporadically, a study suggests.

Read More »

Takeda Alzheimer’s Drug Fails Late-Stage Study

Takeda Pharmaceutical and development partner Zinfandel Pharmaceuticals pulled the plug on their five-year Phase III TOMMORROW trial following an interim analysis.

Read More »

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/MabThera

Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.

Read More »

Amgen Migraine Drug Wows in Late-Stage Study

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage clinical trials.

Read More »

Page 3 of 8412345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation